Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05872620 · ClinicalTrials.gov registry record · Phase 3

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
1,613
Enrollment target
20
Study locations

NCT05872620 is a Phase 3 study of Obesity and Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,613 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05872620, a Phase 3 study of Obesity and Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
1,613 participants
Enrollment target
20
Study locations

Study Summary

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Conditions Studied

Obesity Type 2 Diabetes Overweight

Interventions

  • DRUG Placebo
  • DRUG Orforglipron

Study Locations (20)

California

  • AMCR Institute - Escondido
  • Velocity Clinical Research, Huntington Park - Huntington Park
  • Velocity Clinical Research, Westlake - Los Angeles
  • Catalina Research Institute, LLC - Montclair
  • University Clinical Investigators, Inc. - Tustin

Florida

  • Encore Medical Research - Hollywood
  • East Coast Institute for Research, LLC - Jacksonville
  • South Florida Clinical Research Institute - Margate
  • Suncoast Clinical Research, Inc. - New Port Richey

Georgia

  • Balanced Life Health Care Solutions/SKYCRNG - Lawrenceville
  • Endocrine Research Solutions, Inc. - Roswell
  • North Georgia Clinical Research - Woodstock

Arizona

  • Novak Clinical Research - Tucson - North La Cholla Boulevard - Tucson
  • Yuma Clinical Trials - Yuma

Alabama

  • Cahaba Research - Pelham - Pelham

Hawaii

  • Pacific Diabetes & Endocrine Center - Honolulu

Idaho

  • Solaris Clinical Research - Meridian

Iowa

  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Trial Details

FieldValue
Enrollment Target 1,613 participants
Start Date 2023-06-05
Est. Completion 2025-08-08
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05872620

The ClinicalTrials.gov registry entry for NCT05872620 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,613 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (97% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05872620 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT05872620 about?

NCT05872620 is a clinical study titled "A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes". This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

What is the current status of trial NCT05872620?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,613 participants. The study started on 2023-06-05. Estimated completion is 2025-08-08.

What conditions does trial NCT05872620 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.

What interventions are being tested in trial NCT05872620?

The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).

Who is sponsoring clinical trial NCT05872620?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05872620 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Type 2 Diabetes

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.